Euglena (DB:8EG) - Stock Price, News & Analysis

8EG Stock Overview

Euglena Co., Ltd. engages in the research, development, production, and sale of microalgae in Japan.

8EG fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Risk Analysis

Shareholders have been diluted in the past year

Euglena Co., Ltd. Competitors

Beiersdorf

XTRA:BEI

€31.0b

Beauty Health

NasdaqCM:SKIN

US$397.5m

C&C International

KOSDAQ:A352480

₩815.8b

Glass House Brands

OTCPK:GLAS.F

US$614.7m

Price History & Performance

Summary of all time highs, changes and price drops for Euglena
Historical stock prices
Current Share Price	JP¥3.02
52 Week High	JP¥6.15
52 Week Low	JP¥3.02
Beta	0.057
1 Month Change	-17.93%
3 Month Change	-28.10%
1 Year Change	-48.38%
3 Year Change	-58.34%
5 Year Change	-50.65%
Change since IPO	-46.82%

Recent updates

Shareholder Returns

	8EG	DE Personal Products	DE Market
7D	-3.8%	4.4%	1.7%
1Y	-48.4%	-2.0%	2.3%

Price Volatility

Is 8EG's price volatile compared to industry and market?
8EG volatility
8EG Average Weekly Movement	4.3%
Personal Products Industry Average Movement	4.7%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.1%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 8EG's share price has been volatile over the past 3 months.

Volatility Over Time: 8EG's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2005	846	Tomohiro Wakahara	www.euglena.jp

Euglena Co., Ltd. engages in the research, development, production, and sale of microalgae in Japan. The company operates through two segments, Healthcare Business and Energy/Environment Business. It also manufactures and sells foods and cosmetics using euglena.

Euglena Co., Ltd. Fundamentals Summary

How do Euglena's earnings and revenue compare to its market cap?
8EG fundamental statistics
Market cap	€410.07m
Earnings (TTM)	-€15.90m
Revenue (TTM)	€278.66m

1.5x

P/S Ratio

-25.8x

P/E Ratio

Is 8EG overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
8EG income statement (TTM)
Revenue	JP¥46.48b
Cost of Revenue	JP¥14.71b
Gross Profit	JP¥31.78b
Other Expenses	JP¥34.43b
Earnings	-JP¥2.65b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 13, 2024

Earnings per share (EPS)	-19.70
Gross Margin	68.36%
Net Profit Margin	-5.71%
Debt/Equity Ratio	124.0%

How did 8EG perform over the long term?

See historical performance and comparison

8EG Stock Overview

Rewards

Risk Analysis

Euglena Co., Ltd. Competitors

XTRA:BEI

€31.0b

NasdaqCM:SKIN

US$397.5m

KOSDAQ:A352480

₩815.8b

OTCPK:GLAS.F

US$614.7m

Price History & Performance

Recent News & Updates

Euglena Co., Ltd. to Report Q1, 2024 Results on May 13, 2024

Full year 2023 earnings released: JP¥22.75 loss per share (vs JP¥23.83 loss in FY 2022)

Euglena Co., Ltd., Annual General Meeting, Mar 19, 2024

Full year 2023 earnings released: JP¥22.75 loss per share (vs JP¥23.83 loss in FY 2022)

Zenhoren Co.,Ltd. (TSE:5845) agreed to acquire 18.93% stake in Okinawa Basketball Co., Ltd from Euglena Co., Ltd. (TSE:2931) for ¥360 million.

Euglena Co., Ltd. (TSE:2931) agreed to acquire Saticine Medical Co., Ltd.

Recent updates

Euglena Co., Ltd. to Report Q1, 2024 Results on May 13, 2024

Full year 2023 earnings released: JP¥22.75 loss per share (vs JP¥23.83 loss in FY 2022)

Euglena Co., Ltd., Annual General Meeting, Mar 19, 2024

Full year 2023 earnings released: JP¥22.75 loss per share (vs JP¥23.83 loss in FY 2022)

Zenhoren Co.,Ltd. (TSE:5845) agreed to acquire 18.93% stake in Okinawa Basketball Co., Ltd from Euglena Co., Ltd. (TSE:2931) for ¥360 million.

Euglena Co., Ltd. (TSE:2931) agreed to acquire Saticine Medical Co., Ltd.

Insufficient new directors

Euglena Co., Ltd. to Report Fiscal Year 2023 Results on Feb 14, 2024

Third quarter 2023 earnings released: JP¥2.98 loss per share (vs JP¥15.91 loss in 3Q 2022)

Euglena Co., Ltd. to Report Q3, 2023 Results on Nov 13, 2023

Second quarter 2023 earnings released

Euglena Co., Ltd. to Report Q2, 2023 Results on Aug 14, 2023

First quarter 2023 earnings released

Full year 2022 earnings released: JP¥23.83 loss per share (vs JP¥44.51 loss in FY 2021)

Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending Dec. 31, 2023

Euglena Co., Ltd., Annual General Meeting, Mar 24, 2023

Full year 2022 earnings released: JP¥23.83 loss per share (vs JP¥44.51 loss in FY 2021)

Euglena Co., Ltd. announced that it has received ¥7.7999475 billion in funding from Marui Group Co., Ltd., Rohto Pharmaceutical Co.,Ltd., Mazda Motor Corporation, Dai-ichi Life Holdings, Inc.

Euglena Co., Ltd. announced that it expects to receive ¥7.7999475 billion in funding from Marui Group Co., Ltd., Rohto Pharmaceutical Co.,Ltd.

Euglena Co., Ltd. to Report Fiscal Year 2022 Results on Feb 13, 2023

Euglena Co., Ltd. Provides Consolidated Financial Guidance for the Year Ending December 31, 2022

Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

Euglena Co., Ltd. to Report Q2, 2022 Results on Aug 10, 2022

Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

Euglena Co., Ltd. to Report Q1, 2022 Results on May 13, 2022

Full year 2021 earnings released: JP¥44.51 loss per share (vs JP¥17.15 loss in FY 2020)

Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

Euglena Co., Ltd., Annual General Meeting, Mar 26, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Euglena Co., Ltd. Provides Earnings Guidance for the Period from October 1, 2020 to December 31, 2021

Euglena Co., Ltd. Provides Consolidated Sales Guidance for the Full Year Ending September 30, 2021

Forecast to breakeven in 2022

Second quarter 2021 earnings released: EPS JP¥1.75 (vs JP¥1.17 in 2Q 2020)

Euglena Co., Ltd., Chevron Lummus Global and Applied Research Associates, Inc. Announce Successful Production of Renewable Jet Fuel

Euglena Co., Ltd. to Report Q2, 2021 Results on May 14, 2021

First quarter 2021 earnings released: JP¥3.87 loss per share (vs JP¥2.71 loss in 1Q 2020)

New 90-day high: €7.55

Euglena Co., Ltd. (TSE:2931) entered into an agreement to acquire Liguna, K.K. from Noriko Minamizawa and Takeshi Matsumoto.

Euglena Co., Ltd. to Report Q1, 2021 Results on Feb 15, 2021

Full year 2020 earnings released: JP¥16.00 loss per share

New 90-day low: €6.05

The fund managed by Advantage Partners, Inc., Euglena Co., Ltd. (TSE:2931) and Tokyo Century Corporation (TSE:8439) agreed to acquire Q' Sai Co., Ltd. from Coca-Cola Bottlers Japan Holdings Inc. (TSE:2579).

New 90-day low: €6.30

Full year 2020 earnings released: JP¥16.00 loss per share

Euglena Co., Ltd., Annual General Meeting, Dec 18, 2020

Euglena Co., Ltd. to Report Fiscal Year 2020 Results on Nov 13, 2020

New 90-day high - €7.05

Earnings released

Euglena Co., Ltd. (TSE:2931) cancelled the acquisition of MEJ Inc. from Toru Koga and others.

Shareholder Returns

Price Volatility

About the Company

Euglena Co., Ltd. Fundamentals Summary

1.5x

-25.8x

Earnings & Revenue